端粒选择性延长是异柠檬酸脱氢酶1突变星形细胞瘤的主要端粒维护机制
该研究在46例星形细胞瘤样本中分析细胞特异性端粒长度,发现所有端粒选择性延长(ALT)阳性样本均携带IDH1R132H突变且ATRX表达缺失,而TERT启动子突变与IDH野生型、ATRX表达及短端粒相关;体外实验显示IDH1R132H过表达下调ATRX并导致不依赖TERT的端粒延长。
要点
- 所有ALT阳性星形细胞瘤均无TERT启动子突变、ATRX表达缺失且携带IDH1R132H突变。
- IDH1R132H突变星形细胞瘤的细胞特异性端粒长度显著长于野生型。
- 体外过表达IDH1R132H可下调ATRX并导致不依赖TERT的端粒延长。
核心结论
- ALT是IDH1R132H突变星形细胞瘤的主要端粒维护机制,而TERT启动子突变与IDH野生型胶质瘤相关。
- 体外IDH1R132H下调ATRX表达导致ALT,可能解释IDH1R132H突变、ATRX缺失与ALT之间的强关联。
研究设计与样本
- 研究分析了46例星形细胞瘤样本(WHO II-IV级),采用改良免疫定量荧光原位杂交在单细胞水平检测细胞特异性端粒长度,以内皮细胞作为内参。
- 在同一样本中检测IDH1/TERT启动子突变状态和ATRX表达。
- 体外使用多西环素诱导的IDH1R132H胶质瘤细胞系系统研究IDH1R132H突变与细胞特异性端粒长度的相互作用。
主要发现
- 几乎所有ALT阳性星形细胞瘤均无TERT启动子突变且ATRX表达缺失。
- 所有ALT阳性样本均携带IDH1R132H突变,IDH1R132H胶质瘤的细胞特异性端粒长度显著长于野生型。
- TERT启动子突变与IDH野生型、ATRX表达、无ALT及短细胞特异性端粒长度相关。
- 校正IDH1状态后,ALT、TERT启动子突变和细胞特异性端粒长度均无预后意义。
- 体外LN319胶质瘤细胞系中过表达IDH1R132H导致ATRX下调及快速的、不依赖TERT的端粒延长,与ALT一致。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Isocitrate dehydrogenase 1 (IDH1) mutations are associated with improved survival in gliomas. Depending on the IDH1 status, TERT promoter mutations affect prognosis. IDH1 mutations are associated with alpha-thalassemia/mental retardation syndrome X-linked (ATRX) mutations and alternative lengthening of telomeres (ALT), suggesting an interaction between IDH1 and telomeres. However, little is known how IDH1 mutations affect telomere maintenance. METHODS: We analyzed cell-specific telomere length (CS-TL) on a single cell level in 46 astrocytoma samples (WHO II-IV) by modified immune-quantitative fluorescence in situ hybridization, using endothelial cells as internal reference. In the same samples, we determined IDH1/TERT promoter mutation status and ATRX expression. The interaction of IDH1R132H mutation and CS-TL was studied in vitro using an IDH1R132H doxycycline-inducible glioma cell line system. RESULTS: Virtually all ALTpositive astrocytomas had normal TERT promoter and lacked ATRX expression. Further, all ALTpositive samples had IDH1R132H mutations, resulting in a significantly longer CS-TL of IDH1R132H gliomas, when compared to their wildtype counterparts. Conversely, TERT promotor mutations were associated with IDHwildtype, ATRX expression, lack of ALT and short CS-TL. ALT, TERT promoter mutations, and CS-TL remained without prognostic significance, when correcting for IDH1 status. In vitro, overexpression of IDHR132H in the glioma cell line LN319 resulted in downregulation of ATRX and rapid TERT-independent telomere lengthening consistent with ALT. CONCLUSION: ALT is the major telomere maintenance mechanism in IDHR132H mutated astrocytomas, while TERT promoter mutations were associated with IDHwildtype glioma. IDH1R132H downregulates ATRX expression in vitro resulting in ALT, which may contribute to the strong association of IDH1R132H mutations, ATRX loss, and ALT.
引用
- Ferreira MSV, Sørensen MD, Pusch S, et al. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation. J Neurooncol. 2020. PMID: 31960234. doi:10.1007/s11060-020-03394-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。